Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2018 May 1;36(13):1343-1373.
doi: 10.1200/JCO.2017.76.6394. Epub 2018 Jan 18.

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline

Hedy L Kindler  1 , Nofisat Ismaila  1 , Samuel G Armato 3rd  1 , Raphael Bueno  1 , Mary Hesdorffer  1 , Thierry Jahan  1 , Clyde Michael Jones  1 , Markku Miettinen  1 , Harvey Pass  1 , Andreas Rimner  1 , Valerie Rusch  1 , Daniel Sterman  1 , Anish Thomas  1 , Raffit Hassan  1
Affiliations
Practice Guideline

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline

Hedy L Kindler et al. J Clin Oncol. .

Abstract

Purpose To provide evidence-based recommendations to practicing physicians and others on the management of malignant pleural mesothelioma. Methods ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, pathology, imaging, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 1990 through 2017. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. Results The literature search identified 222 relevant studies to inform the evidence base for this guideline. Recommendations Evidence-based recommendations were developed for diagnosis, staging, chemotherapy, surgical cytoreduction, radiation therapy, and multimodality therapy in patients with malignant pleural mesothelioma. Additional information is available at www.asco.org/thoracic-cancer-guidelines and www.asco.org/guidelineswiki .

PubMed Disclaimer

Conflict of interest statement

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Figures

Fig 1.
Fig 1.
Study flow diagram.
See this image and copyright information in PMC

Comment in

References

    1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al.: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636–2644, 2003 - PubMed
    1. Shiffman RN, Michel G, Rosenfeld RM, et al.: Building better guidelines with BRIDGE-Wiz: Development and evaluation of a software assistant to promote clarity, transparency, and implementability. J Am Med Inform Assoc 19:94–101, 2012 - PMC - PubMed
    1. Krug LM, Kindler HL, Calvert H, et al.: Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): A phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol 16:447–456, 2015 - PubMed
    1. Treasure T, Lang-Lazdunski L, Waller D, et al.: Extra-pleural pneumonectomy versus no extrapleural pneumonectomy for patients with malignant pleural mesothelioma: Clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 12:763–772, 2011 - PMC - PubMed
    1. Metintas M, Ak G, Dundar E, et al.: Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: A randomized, controlled trial. Chest 137: 1362–1368, 2010 - PubMed

Publication types